BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rich NE, John BV, Parikh ND, Rowe I, Mehta N, Khatri G, Thomas SM, Anis M, Mendiratta-Lala M, Hernandez C, Odewole M, Sundaram LT, Konjeti VR, Shetty S, Shah T, Zhu H, Yopp AC, Hoshida Y, Yao FY, Marrero JA, Singal AG. Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. Hepatology 2020;72:1654-65. [PMID: 32017165 DOI: 10.1002/hep.31159] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 28.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang H, Mao Y, Huang M. Letter to the Editor: Should Growth Pattern of Hepatocellular Carcinoma Be Constant and Homogenous? Hepatology 2021;73:2617-8. [PMID: 33205459 DOI: 10.1002/hep.31640] [Reference Citation Analysis]
2 Rich NE, Singal AG. Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines? Hepatology 2022;75:740-53. [PMID: 34923659 DOI: 10.1002/hep.32284] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Mehta N, Parikh ND, Kelley RK, Hameed B, Singal AG. Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. Clin Gastroenterol Hepatol 2021;19:1520-30. [PMID: 32652308 DOI: 10.1016/j.cgh.2020.06.072] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
4 Barry A, Apisarnthanarax S, O'Kane GM, Sapisochin G, Beecroft R, Salem R, Yoon SM, Lim YS, Bridgewater J, Davidson B, Scorsetti M, Solbiati L, Diehl A, Schuffenegger PM, Sham JG, Cavallucci D, Galvin Z, Dawson LA, Hawkins MA. Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. Lancet Gastroenterol Hepatol. 2020;5:765-775. [PMID: 32511951 DOI: 10.1016/s2468-1253(20)30182-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 11.5] [Reference Citation Analysis]
5 Hamid S, Alvares da Silva MR, Burak KW, Chen T, Drenth JPH, Esmat G, Gaspar R, LaBrecque D, Lee A, Macedo G, McMahon B, Ning Q, Reau N, Sonderup M, van Leeuwen DJ, Armstrong D, Yurdaydin C. WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. J Clin Gastroenterol. 2021;55:1-11. [PMID: 33230011 DOI: 10.1097/mcg.0000000000001459] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
6 Choi DT, Davila JA, Sansgiry S, David E, Singh H, El-Serag HB, Hsiao-Fan Sada Y. Factors Associated With Delay of Diagnosis of Hepatocellular Carcinoma in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021;19:1679-87. [PMID: 32693047 DOI: 10.1016/j.cgh.2020.07.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
7 Del Poggio P, Mazzoleni M, Lazzaroni S, D'Alessio A. Surveillance for hepatocellular carcinoma at the community level: Easier said than done. World J Gastroenterol 2021; 27(37): 6180-6190 [PMID: 34712026 DOI: 10.3748/wjg.v27.i37.6180] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Singal AG, El-Serag HB. Rational HCC screening approaches for patients with NAFLD. J Hepatol 2021:S0168-8278(21)02026-2. [PMID: 34508791 DOI: 10.1016/j.jhep.2021.08.028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
9 John BV. No Association Between Direct-Acting Antivirals and Hepatocellular Carcinoma Progression on the Waiting List: Time to Put This Controversy to Rest? Liver Transpl 2020;26:621-3. [PMID: 32147956 DOI: 10.1002/lt.25746] [Reference Citation Analysis]
10 Mehta N, Dodge JL, Roberts JP, Yao FY. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival. J Hepatol 2021;74:829-37. [PMID: 33188904 DOI: 10.1016/j.jhep.2020.10.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Fancellu A, Sanna V, Scognamillo F, Feo CF, Vidili G, Nigri G, Porcu A. Surgical treatment of hepatocellular carcinoma in the era of COVID-19 pandemic: A comprehensive review of current recommendations. World J Clin Cases 2021; 9(15): 3517-3530 [PMID: 34046452 DOI: 10.12998/wjcc.v9.i15.3517] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Lee YT, Wang JJ, Luu M, Noureddin M, Kosari K, Agopian VG, Rich NE, Lu SC, Tseng HR, Nissen NN, Singal AG, Yang JD. The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. J Natl Cancer Inst 2021:djab079. [PMID: 34010422 DOI: 10.1093/jnci/djab079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Cho JY, Kim SS, Lee YS, Song DS, Lee JH, Kim JH. Management of liver diseases during the pandemic of coronavirus disease-19. Clin Mol Hepatol 2020;26:243-50. [PMID: 32570302 DOI: 10.3350/cmh.2020.0111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Singal AG, Lok AS, Feng Z, Kanwal F, Parikh ND. Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31297-0. [PMID: 32961340 DOI: 10.1016/j.cgh.2020.09.036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
15 Rich NE, Phen S, Desai N, Mittal S, Yopp AC, Yang JD, Marrero JA, Iyengar P, Infante RE, Singal AG. Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01036-3. [PMID: 34555519 DOI: 10.1016/j.cgh.2021.09.022] [Reference Citation Analysis]
16 Rich NE, Parvathaneni A, Sen A, Odewole M, Arroyo A, Mufti AR, Kerr TA, Grant L, Tujios SR, Mayo MJ, Lee WM, Yang JD, Yokoo T, Gopal P, Hoshida Y, Zhu H, Yopp AC, Marrero JA, Singal AG. High Neutrophil-Lymphocyte Ratio and Delta Neutrophil-Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer. Dig Dis Sci 2021. [PMID: 33939138 DOI: 10.1007/s10620-021-07001-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Cai Y, Zheng Q, Yao DJ. Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 is a diagnostic and prognostic biomarker for hepatocellular carcinoma. World J Clin Cases 2020; 8(17): 3774-3785 [PMID: 32953853 DOI: 10.12998/wjcc.v8.i17.3774] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Harding-Theobald E, Louissaint J, Maraj B, Cuaresma E, Townsend W, Mendiratta-Lala M, Singal AG, Su GL, Lok AS, Parikh ND. Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma. Aliment Pharmacol Ther 2021;54:890-901. [PMID: 34390014 DOI: 10.1111/apt.16563] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
19 Denys A, Guiu B, Chevallier P, Digklia A, de Kerviler E, de Baere T. Interventional oncology at the time of COVID-19 pandemic: Problems and solutions. Diagn Interv Imaging. 2020;101:347-353. [PMID: 32360351 DOI: 10.1016/j.diii.2020.04.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
20 Li B, Zhao Y, Cai W, Ming A, Li H. Validation and update of a multivariable prediction model for the identification and management of patients at risk for hepatocellular carcinoma. Clin Proteomics 2021;18:21. [PMID: 34412596 DOI: 10.1186/s12014-021-09326-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Rich NE, Carr C, Yopp AC, Marrero JA, Singal AG. Racial and Ethnic Disparities in Survival Among Patients With Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31725-0. [PMID: 33387668 DOI: 10.1016/j.cgh.2020.12.029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
22 Osho A, Rich NE, Singal AG. Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. Hepatoma Res 2020;6:55. [PMID: 32944652 DOI: 10.20517/2394-5079.2020.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Kwong A, Hameed B, Syed S, Ho R, Mard H, Arshad S, Ho I, Suleman T, Yao F, Mehta N. Machine learning to predict waitlist dropout among liver transplant candidates with hepatocellular carcinoma. Cancer Medicine. [DOI: 10.1002/cam4.4538] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, Yang JD, Reig M, Cabibbo G, Nahon P, Parikh ND, Marrero JA. HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
25 Rich NE, Marrero JA, Singal AG. REPLY. Hepatology 2021;73:2618-9. [PMID: 33205463 DOI: 10.1002/hep.31638] [Reference Citation Analysis]
26 Onyirioha K, Mittal S, G Singal A. Is hepatocellular carcinoma surveillance in high-risk populations effective? Hepat Oncol 2020;7:HEP25. [PMID: 32774835 DOI: 10.2217/hep-2020-0012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Zhang G, Su L, Lv X, Yang Q. A novel tumor doubling time-related immune gene signature for prognosis prediction in hepatocellular carcinoma. Cancer Cell Int 2021;21:522. [PMID: 34627241 DOI: 10.1186/s12935-021-02227-w] [Reference Citation Analysis]
28 d’Abadie P, Walrand S, Lhommel R, Hesse M, Borbath I, Jamar F. Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria. Current Oncology 2022;29:2422-34. [DOI: 10.3390/curroncol29040196] [Reference Citation Analysis]
29 Oikonomou KG, Papamichalis P, Zafeiridis T, Xanthoudaki M, Papapostolou E, Valsamaki A, Bouliaris K, Papamichalis M, Karvouniaris M, Vlachostergios PJ, Skoura AL, Komnos A. Gastroenterology and liver disease during COVID-19 and in anticipation of post-COVID-19 era: Current practice and future directions. World J Clin Cases 2021; 9(19): 4918-4938 [PMID: 34307544 DOI: 10.12998/wjcc.v9.i19.4918] [Reference Citation Analysis]
30 Toyoda H, Hiraoka A, Olivares J, Al-Jarrah T, Devlin P, Kaneoka Y, Maeda A, Yopp AC, Parikh ND, Singal AG. Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31491-9. [PMID: 33295281 DOI: 10.1016/j.cgh.2020.10.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Rosenblatt R, Verna EC. COVID 19: Management of Decompensated Cirrhosis and Liver Transplant Recipients. Clin Liver Dis (Hoboken). 2020;15:200-203. [PMID: 32537136 DOI: 10.1002/cld.968] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
32 Kim JH, Yoon JH, Joo I, Lee JM. Evaluation of Primary Liver Cancers Using Hepatocyte-Specific Contrast-Enhanced MRI: Pitfalls and Potential Tips. J Magn Reson Imaging 2021;53:655-75. [PMID: 32700807 DOI: 10.1002/jmri.27213] [Reference Citation Analysis]
33 Tapper EB, Asrani SK. The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. J Hepatol. 2020;73:441-445. [PMID: 32298769 DOI: 10.1016/j.jhep.2020.04.005] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 35.0] [Reference Citation Analysis]
34 Chang YS, Shen YC, Chen JH, Chang CC. Reply to C.-H. Chiang et al and R. Chang et al. J Clin Oncol 2022;:JCO2200711. [PMID: 35549388 DOI: 10.1200/JCO.22.00711] [Reference Citation Analysis]
35 Sanchez JI, Jiao J, Kwan SY, Veillon L, Warmoes MO, Tan L, Odewole M, Rich NE, Wei P, Lorenzi PL, Singal AG, Beretta L. Lipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prev Res (Phila) 2021;14:955-62. [PMID: 34253566 DOI: 10.1158/1940-6207.CAPR-20-0612] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology 2020;72:287-304. [PMID: 32298473 DOI: 10.1002/hep.31281] [Cited by in Crossref: 231] [Cited by in F6Publishing: 239] [Article Influence: 115.5] [Reference Citation Analysis]
37 Govalan R, Luu M, Lauzon M, Kosari K, Ahn JC, Rich NE, Nissen N, Roberts LR, Singal AG, Yang JD. Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact. Hepatol Commun 2021. [PMID: 34558830 DOI: 10.1002/hep4.1795] [Reference Citation Analysis]
38 Jaffe A, Schilsky ML, Deshpande R, Batra R. Liver Transplantation in the Time of COVID19: Barriers and Ethical considerations for Management and Next Steps. Hepatol Commun. 2020;. [PMID: 32838103 DOI: 10.1002/hep4.1568] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
39 Singal AG, Tayob N, Mehta A, Marrero JA, El-Serag H, Jin Q, Saenz de Viteri C, Fobar A, Parikh ND. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology 2022;75:541-9. [PMID: 34618932 DOI: 10.1002/hep.32185] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
40 Singal AG, Hoshida Y, Pinato DJ, Marrero J, Nault JC, Paradis V, Tayob N, Sherman M, Lim YS, Feng Z, Lok AS, Rinaudo JA, Srivastava S, Llovet JM, Villanueva A. International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology 2021;160:2572-84. [PMID: 33705745 DOI: 10.1053/j.gastro.2021.01.233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
41 Ajayi F, Jan J, Singal AG, Rich NE. Racial and Sex Disparities in Hepatocellular Carcinoma in the USA. Curr Hepatol Rep 2020;19:462-9. [PMID: 33828937 DOI: 10.1007/s11901-020-00554-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Melendez-Torres J, Singal AG. Early detection of hepatocellular carcinoma: roadmap for improvement. Expert Rev Anticancer Ther 2022. [PMID: 35514249 DOI: 10.1080/14737140.2022.2074404] [Reference Citation Analysis]
43 Spearman CW, Aghemo A, Valenti L, Sonderup MW. COVID-19 and the liver: A 2021 update. Liver Int 2021;41:1988-98. [PMID: 34152690 DOI: 10.1111/liv.14984] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Wagle NS, Park S, Washburn D, Ohsfeldt RL, Rich NE, Singal AG, Kum HC. Racial, Ethnic, and Socioeconomic Disparities in Curative Treatment Receipt and Survival in Hepatocellular Carcinoma. Hepatol Commun 2021. [PMID: 34796703 DOI: 10.1002/hep4.1863] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Muñoz-Martínez S, Sapena V, Forner A, Nault JC, Sapisochin G, Rimassa L, Sangro B, Bruix J, Sanduzzi-Zamparelli M, Hołówko W, El Kassas M, Mocan T, Bouattour M, Merle P, Hoogwater FJH, Alqahtani SA, Reeves HL, Pinato DJ, Giorgakis E, Meyer T, Villadsen GE, Wege H, Salati M, Mínguez B, Di Costanzo GG, Roderburg C, Tacke F, Varela M, Galle PR, Alvares-da-Silva MR, Trojan J, Bridgewater J, Cabibbo G, Toso C, Lachenmayer A, Casadei-Gardini A, Toyoda H, Lüdde T, Villani R, Matilla Peña AM, Guedes Leal CR, Ronzoni M, Delgado M, Perelló C, Pascual S, Lledó JL, Argemi J, Basu B, da Fonseca L, Acevedo J, Siebenhüner AR, Braconi C, Meyers BM, Granito A, Sala M, Rodríguez-Lope C, Blaise L, Romero-Gómez M, Piñero F, Gomez D, Mello V, Pinheiro Alves RC, França A, Branco F, Brandi G, Pereira G, Coll S, Guarino M, Benítez C, Anders MM, Bandi JC, Vergara M, Calvo M, Peck-Radosavljevic M, García-Juárez I, Cardinale V, Lozano M, Gambato M, Okolicsanyi S, Morales-Arraez D, Elvevi A, Muñoz AE, Lué A, Iavarone M, Reig M. Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Rep 2021;3:100260. [PMID: 33644725 DOI: 10.1016/j.jhepr.2021.100260] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
46 Fujiwara N, Kobayashi M, Fobar AJ, Hoshida A, Marquez CA, Koneru B, Panda G, Taguri M, Qian T, Raman I, Li QZ, Hoshida H, Sezaki H, Kumada H, Tateishi R, Yokoo T, Yopp AC, Chung RT, Fuchs BC, Baumert TF, Marrero JA, Parikh ND, Zhu S, Singal AG, Hoshida Y. A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. Med (N Y) 2021;2:836-850.e10. [PMID: 34318286 DOI: 10.1016/j.medj.2021.03.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
47 Cheng H, Yang X, Liu G. Superstable homogeneous iodinated formulation technology: revolutionizing transcatheter arterial chemoembolization. Science Bulletin 2020;65:1685-7. [DOI: 10.1016/j.scib.2020.06.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
48 Rich NE, Murphy CC, Yopp AC, Tiro J, Marrero JA, Singal AG. Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma. Aliment Pharmacol Ther 2020;52:701-9. [PMID: 32598091 DOI: 10.1111/apt.15917] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
49 Bollipo S, Kapuria D, Rabiee A, Ben-Yakov G, Lui RN, Lee HW, Kumar G, Siau K, Turnes J, Dhanasekaran R. One world, one pandemic, many guidelines: management of liver diseases during COVID-19. Gut 2020;69:1369-72. [PMID: 32499304 DOI: 10.1136/gutjnl-2020-321553] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 15.5] [Reference Citation Analysis]
50 Lee SE, Alcedo KP, Kim HJ, Snider NT. Alternative Splicing in Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol. 2020;10:699-712. [PMID: 32389640 DOI: 10.1016/j.jcmgh.2020.04.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
51 Benhammou JN, Lin J, Aby ES, Markovic D, Raman SS, Lu DS, Tong MJ. Nonalcoholic fatty liver disease-related hepatocellular carcinoma growth rates and their clinical outcomes. Hepatoma Res 2021;7:70. [PMID: 34966854 DOI: 10.20517/2394-5079.2021.74] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
52 Nathani P, Gopal P, Rich N, Yopp A, Yokoo T, John B, Marrero J, Parikh N, Singal AG. Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. Gut 2021;70:401-7. [PMID: 32398224 DOI: 10.1136/gutjnl-2020-321040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]